Dalteparin (Fragmin, Pfizer) for the extended treatment of symptomatic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary embolus) to prevent recurrent venous thromboembolism in patients with cancer

Recommendations for approval

Recommendations against approval

Nonapprovable designations

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Pipeline Preview (October 2006)

Newsletter